Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and The Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and The Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Mol Cell. 2013 Dec 26;52(6):769-82. doi: 10.1016/j.molcel.2013.10.022. Epub 2013 Nov 21.
Histone deacetylases (HDACs) are believed to regulate gene transcription by catalyzing deacetylation reactions. HDAC3 depletion in mouse liver upregulates lipogenic genes and results in severe hepatosteatosis. Here we show that pharmacologic HDAC inhibition in primary hepatocytes causes histone hyperacetylation but does not upregulate expression of HDAC3 target genes. Meanwhile, deacetylase-dead HDAC3 mutants can rescue hepatosteatosis and repress lipogenic genes expression in HDAC3-depleted mouse liver, demonstrating that histone acetylation is insufficient to activate gene transcription. Mutations abolishing interactions with the nuclear receptor corepressor (NCOR or SMRT) render HDAC3 nonfunctional in vivo. Additionally, liver-specific knockout of NCOR, but not SMRT, causes metabolic and transcriptomal alterations resembling those of mice without hepatic HDAC3, demonstrating that interaction with NCOR is essential for deacetylase-independent function of HDAC3. These findings highlight nonenzymatic roles of a major HDAC in transcriptional regulation in vivo and warrant reconsideration of the mechanism of action of HDAC inhibitors.
组蛋白去乙酰化酶 (HDACs) 被认为通过催化去乙酰化反应来调节基因转录。在小鼠肝脏中耗尽 HDAC3 会上调脂肪生成基因,导致严重的肝脂肪变性。在这里,我们表明在原代肝细胞中使用药物抑制 HDAC 会导致组蛋白过度乙酰化,但不会上调 HDAC3 靶基因的表达。同时,去乙酰化酶失活的 HDAC3 突变体可以挽救 HDAC3 耗尽的小鼠肝脏中的肝脂肪变性并抑制脂肪生成基因的表达,表明组蛋白乙酰化不足以激活基因转录。与核受体辅抑制因子 (NCOR 或 SMRT) 的相互作用丧失的突变使 HDAC3 在体内失去功能。此外,肝脏特异性敲除 NCOR,但不是 SMRT,会导致代谢和转录组改变,类似于没有肝 HDAC3 的小鼠,表明与 NCOR 的相互作用对于 HDAC3 的去乙酰化酶非依赖性功能是必需的。这些发现强调了主要 HDAC 在体内转录调控中的非酶促作用,并需要重新考虑 HDAC 抑制剂的作用机制。